|View printer-friendly version|
|Wright Medical Group, Inc. To Highlight Foot and Ankle Product Innovations at the 2009 American College of Foot and Ankle Surgeons Meeting|
INBONE™ Total Ankle System: Experience the Elegance of IM Guidance
The INBONE™ Total Ankle System is the only ankle replacement system on the market utilizing intramedullary guidance instrumentation and in-situ assembly of the modular ankle implants. These unique features help reduce the “learning curve” associated with traditional ankle replacement systems, thus allowing accurate and highly-stable implant placement.
ENDO-FUSE™ Intra-osseous Fusion System: Achieve Fusion from the Inside Out
The Company’s new ENDO-FUSE™ Intra-osseous Fusion System offers a unique approach to fusion and osteotomy fixation of joints in the foot. The ENDO-FUSE™ system features both “beam” and “rod” shaped implants that are designed to reside completely within the bone, thus eliminating the possibility of irritation to tendons and soft-tissues. Made of titanium, ENDO-FUSE™ implants’ plasma coated surface allows bone on-growth across the entire surface of the device. This creates the opportunity for greater fixation and a stable environment for fusion to occur.
G-FORCE™ Foot and Ankle Tenodesis System: High Strength and Radiolucent
With approximately 120,000 foot and ankle soft-tissue fixation procedures performed annually in the U.S., the need for advanced soft tissue fixation devices is extensive. The G-FORCE™ Tenodesis System represents an advanced treatment option for the repair of damaged tendons, and re-routing or “transfer” of tendons of the foot. Key features include streamlined instrumentation which allows optimal tendon tensioning, high fixation strength (demonstrated as up to 35% stronger than the leading competitive device), and a radiolucent PEEK Optima® implant material. The G-FORCE™ Tenodesis System will offer unique screw sizes and instruments specifically designed for foot and ankle surgical applications.
BIOFOAM™ Foot and Ankle Wedge System: Porous Titanium that Mimics Human Bone
With the new BIOFOAM™ Evans Wedge System for corrective osteotomies of the foot, Wright is bringing its clinically-proven, proprietary BIOFOAM™ CANCELLOUS TITANIUM™ technology to the foot and ankle surgeon. This innovative material mimics the strength and flexibility of human bone, while providing an ideal environment for rapid bone in-growth and sustained rigid fixation. BIOFOAM™ implants are sized specifically for bone corrective procedures such as “Evans lengthening” and “Cotton osteotomy” procedures popular for treating patients with advanced flatfoot deformity. The sterile BIOFOAM™ implants eliminate the risk of adverse immune response associated with traditional allografts or the patient morbidity associated with autograft harvest — the current standard of care for these procedures.
Additionally with pre-configured implants and sizing trials, BIOFOAM™ wedges eliminate the timely process of shaping traditional grafts for proper fit, thus speeding the surgical case.
CHARLOTTE™ Lisfranc Reconstruction System: Procedure-Specific System for Lisfranc Repair
Wright’s new Lisfranc system offers surgeons a unique solution to surgical reconstruction of Lisfranc injuries to the foot. Typically an athletic injury that damages key ligaments that support the bones in the middle of the foot, Lisfranc injuries have historically lacked sophisticated surgical implants optimized for this challenging repair. The introduction of the new CHARLOTTE™ Lisfranc system provides surgeons, for the first time, specialized screw and plate designs and patent-pending targeting instrumentation to help improve the clinical outcomes for their patients. This system typifies Wright’s commitment to targeting specific injuries and developing procedure-specific systems to make the procedure more efficient and reliable.
“With intense focus and commitment over the last several years, Wright
has now established itself as the leading company for foot and ankle
surgical products. We are excited to highlight our most recent
innovations, along with our expansive existing portfolio of products, to
surgeons attending the ACFAS meeting later this week in
This press release contains “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
All statements made in this press release, other than statements
of historical fact, are forward-looking statements. Forward-looking
statements reflect management's current knowledge, assumptions, beliefs,
estimates, and expectations and express management's current views of
future performance, results, and trends and may be identified by their
use of terms such as “anticipate,” “believe,” “could,” “estimate,”
“expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” and
other similar terms. The Company wishes to caution readers that actual
results might differ materially from those described in the
forward-looking statements. Forward-looking statements are subject to a
number of risks and uncertainties, including the factors discussed in
the Company’s filings with the
Wright Medical Group, Inc.